287 related articles for article (PubMed ID: 35638418)
1. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
Ripp J; Hentzen S; Saeed A
Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
3. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
6. Arenavirus Therapy in Combination with Checkpoint Blockade as an Effective Way for Better Tumour Clearance.
Bhat H; Ali M; Hamdan TA
Cell Physiol Biochem; 2021 Nov; 55(6):726-738. PubMed ID: 34816678
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
9. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F
Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
Hwang JK; Hong J; Yun CO
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
[TBL] [Abstract][Full Text] [Related]
12. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
13. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic vaccinia virus and cancer immunotherapy.
Xu L; Sun H; Lemoine NR; Xuan Y; Wang P
Front Immunol; 2023; 14():1324744. PubMed ID: 38283361
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
16. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
17. Modeling Oncolytic Viral Therapy, Immune Checkpoint Inhibition, and the Complex Dynamics of Innate and Adaptive Immunity in Glioblastoma Treatment.
Storey KM; Lawler SE; Jackson TL
Front Physiol; 2020; 11():151. PubMed ID: 32194436
[TBL] [Abstract][Full Text] [Related]
18. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
[TBL] [Abstract][Full Text] [Related]
19. Talimogene laherparepvec: First in class oncolytic virotherapy.
Conry RM; Westbrook B; McKee S; Norwood TG
Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123
[TBL] [Abstract][Full Text] [Related]
20. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.
Najafi S; Majidpoor J; Mortezaee K
Biomed Pharmacother; 2023 May; 161():114436. PubMed ID: 36841031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
